IART · Integra LifeSciences Holdings Corporation

The thesis

Integra LifeSciences held its full-year 2026 guidance at the 21 October 2026 third-quarter report, but its fourth-quarter outlook came in below analyst estimates and five brokers cut price targets the next day. The shares stay a recovery story on probation. The fourth-quarter SurgiMend relaunch and the Cincinnati plant's return to full output in the second quarter of 2027 settle whether earnings follow.

The narrative is maturing: the turnaround is well known, and the 2 October 2026 flood update plus the 21 October 2026 report have pushed the payoff further out. Integra reported third-quarter revenue of $411.2 million, up 2.5% organically, and adjusted earnings per share of $0.59 (company press release, 21 October 2026). Analyst consensus, as quoted in company news that day, was $0.56 for earnings and $414.12 million for sales. The adjusted close was $12.32 on 22 October 2026, against $13.44 on 9 October 2026 and a 52-week high of $19.85.

The published rating stays low. The quarter matched the numbers Integra pre-announced on 2 October 2026, so the guidance affirmation carried little new information. The fourth-quarter guide and the higher cost of debt are the new negatives.

Bullish and bearish views on Integra LifeSciences Holdings Corporation

The bull case on Integra LifeSciences Holdings Corporation (IART), in brief: Guidance held at the low end. The bear case: Fourth-quarter guidance is below estimates.

Bull case

• Guidance held at the low end. Integra affirmed full-year adjusted earnings per share of $2.30–$2.40 and revenue of $1.634–$1.654 billion on 21 October 2026. Both ranges match the 2 October 2026 cut, so the flood did not trigger a second reduction.
• Neurosurgery is growing. Specialty Surgery revenue was $304.1 million in the third quarter, up 4.2% organically, with Neuro up 6.5% organically (21 October 2026 release).
• Cash generation is strong. Third-quarter operating cash flow was $96.0 million, and full-year operating cash flow is guided to about $190–$200 million (21 October 2026 release). The company's consolidated total leverage ratio was 3.8 times.
• One broker, Citizens, kept Market Outperform on 22 October 2026 with a $22 target.
• Debt maturities are addressed. Integra closed a $2.1 billion refinancing on 19 October 2026, including a $450 million 9.5% senior secured notes offering due 2033. The maximum net leverage covenant was raised temporarily and steps down to 4.25 times in 2027, from 4.0 times before.

Bear case

• Fourth-quarter guidance is below estimates. Integra guided fourth-quarter adjusted earnings per share to $0.61–$0.71 against a $0.76 analyst estimate, and revenue to $413–$433 million against $436.77 million (company news, 21 October 2026). Management's range implies organic revenue between down 5.1% and down 0.4%.
• Third-quarter sales missed. Revenue of $411.18 million fell short of the $414.12 million analyst estimate (company news, 21 October 2026).
• Tissue Reconstruction is shrinking. Segment revenue was $107.1 million in the third quarter, down 2.2% organically, and Wound Reconstruction Solutions fell 2.9% reported (21 October 2026 release).
• Financing costs rise. Integra expects the effective interest rate to increase near the high end of a 100–200 basis point range after the refinancing (21 October 2026 release). The 9.5% coupon on the new notes is the visible marker.
• Analysts are cutting targets. On 22 October 2026 Citigroup (Neutral) and BMO Capital (Market Perform) moved to $14, Wells Fargo (Equal-Weight) to $13, JP Morgan (Underweight) to $14 and Citizens to $22. Truist (Hold) cut to $15 on 14 October 2026.

Price setup

The adjusted close was $12.32 on 22 October 2026. That is 37.9% below the 52-week high of $19.85, and the shares have fallen 36.9% over three months. The 14-day relative strength index, which measures recent buying against selling on a 0–100 scale, was 46.9, a neutral reading.

The close sits 2.7% above $12.00, the level that ends the case. The 9 October 2026 close of $13.44 and the $16.12 close of 25 September 2026 show the decline has continued past the 2 October 2026 guidance cut.

Crowding evidence points the other way from a crowded long. Four of the six brokers named above sit at neutral or below, one is Underweight, and the earnings date has passed. The one wide outlier is Citizens' $22 target, 78.6% above the last close. No insider-transaction or share-issuance data are available for this note.

Catalysts, next 30 days

• No scheduled company report falls before 22 November 2026. The third-quarter results landed on 21 October 2026, and the next quarterly report is expected around ~2027-02 (est.).
• Quarterly filing. Integra's 10-Q for the third quarter, when filed, will carry the refinancing terms and flood insurance detail in full. The date is not confirmed.
• 31 December 2026 (fourth quarter): management's target for the SurgiMend relaunch, with Braintree transition work continuing.

Elapsed catalysts

• Second quarter of 2027: the date Integra gave on 2 October 2026 for full manufacturing output at Cincinnati. (passed 35d ago)

What would change the view

The case breaks if Integra cuts full-year 2026 guidance again, moves the SurgiMend relaunch beyond the fourth quarter of 2026, or pushes the Cincinnati restart past the second quarter of 2027. A fourth-quarter result at or below the low end of the $0.61–$0.71 adjusted earnings range would also weaken it. A daily close below $12.00 would end the thesis on price.

The case improves if fourth-quarter revenue lands in the upper half of the $413–$433 million range, if insurance recoveries are quantified and cover the lost earnings, and if leverage moves down from 3.8 times despite the higher interest bill.

What it trades with

Integra trades with mid-cap medical-device and hospital-procedure names, where elective surgery volumes and hospital capital spending drive sentiment. Its share price also depends on company-specific items: plant recovery, FDA quality-system remediation after the 19 December 2024 warning letter, and refinancing. The high-yield market matters now because the new notes carry a 9.5% coupon. No peer price comparison is included in this note.